IGM Biosciences, Inc. (IGMS)
NASDAQ: IGMS · IEX Real-Time Price · USD
6.75
-0.45 (-6.25%)
Apr 22, 2024, 4:00 PM EDT - Market closed
IGM Biosciences Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for IGM Biosciences stock have an average target of 17.25, with a low estimate of 8.00 and a high estimate of 25. The average target predicts an increase of 155.56% from the current stock price of 6.75.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for IGMS stock from 9 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 2 | 2 | 2 |
| Hold | 4 | 6 | 6 | 5 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 9 | 9 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $12 | Hold | Reiterates | $12 | +77.78% | Apr 18, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Maintains $7 → $12 | Hold | Maintains | $7 → $12 | +77.78% | Mar 12, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $21 | Buy | Reiterates | $21 | +211.11% | Mar 8, 2024 |
| Wedbush | Wedbush | Buy Reiterates $20 | Buy | Reiterates | $20 | +196.30% | Mar 8, 2024 |
| RBC Capital | RBC Capital | Hold → Buy Upgrades $9 → $21 | Hold → Buy | Upgrades | $9 → $21 | +211.11% | Feb 9, 2024 |
Financial Forecast
Revenue This Year
3.10M
from 2.13M
Increased by 45.40%
Revenue Next Year
10.87M
from 3.10M
Increased by 250.95%
EPS This Year
-3.28
from -4.71
EPS Next Year
-2.93
from -3.28
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 3.6M | 51.2M | 137.0M | 465.0M | 666.5M |
| Avg | 3.1M | 10.9M | 58.9M | 230.9M | 359.2M |
| Low | 2.8M | n/a | n/a | 3.9M | 37.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 68.8% | 1,552.8% | 1,160.7% | 689.5% | 188.7% |
| Avg | 45.4% | 251.0% | 441.9% | 292.0% | 55.6% |
| Low | 33.4% | - | - | -93.3% | -83.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.96 | -2.14 | -1.75 | -2.01 | -1.79 |
| Avg | -3.28 | -2.93 | -2.32 | -1.95 | -1.73 |
| Low | -3.32 | -3.41 | -3.15 | -1.87 | -1.67 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.